Welcome to another episode of Patients Win! Today, we’re diving into the evolving world of direct specialty care with Dr. Sean Stanga, an allergist who’s redefining patient access and transparency in allergy and immunology. Joined by hosts Dr. Jonathan Bushman and Troy Reichert, we explore the pitfalls of traditional hospital employment, from RVU-driven patient churn to inadequate reimbursement for complex specialty procedures, and how direct care models offer a refreshing alternative. Dr. Stanga shares his journey from hospital-based pediatrics in North Dakota to pioneering a direct specialty allergy practice in Iowa, breaking down why patients and providers alike are gravitating towards transparent pricing, reduced wait times, and a restored focus on quality, unhurried care. We’ll hear about innovative therapies like intralymphatic immunotherapy, the real impact of insurance reimbursement limitations, and why so many specialists are now reaching out to learn how they too can bring joy and better outcomes back to their practices. If you’re curious about the future of specialty care, and what happens when patients - and doctors - finally “win,” stay tuned! Link to Dr. Stanga's Specialty Clinic - allergenix.com/patientswin Timestamps: 00:00 Considering a Career in Neonatology 05:55 Challenges of RVUs in Allergy Care 07:37 Impact of RVUs on Allergists 11:30 Explaining the RUC Committee 16:32 Insurance misunderstandings in allergy specialty 19:32 Benefits of direct care 21:18 Pricing and educating in healthcare 26:37 Health insurance and personal autonomy 28:13 Transparent pricing in medical practice 31:12 Telemedicine and cross-state licensing 35:35 New allergy treatment method 39:09 Discussing allergy treatment options 40:48 Intralymphatic method explained 45:07 Challenges in Offering Specialized Allergy Treatment 47:07 Experiences with European medical treatments 50:34 Future topics and direct care benefits Show Website - https://thepatientswin.com/ Primed Healthcare - https://primedhealthcare.com/ Troy Reichert - Show Host - LinkedIn - https://www.linkedin.com/in/troy-reichert-67606b5/ Dr. Jonathan Bushman - Show Host - LinkedIn - https://www.linkedin.com/in/jonathan-bushman-do-106821191 Media Partner - TopHealth - https://tophealth.care/ “Disclaimer: Informational only. Not medical advice. Consult your doctor for guidance.”
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00What people are valuing, and the reason people are coming to DirectCare is because number one, the wait time. They don't have to wait nearly as long to get in to see us. And number two, the transparency. So they like transparency. And transparency is exactly what you can achieve with direct care. Ergo, we have all of our prices listed online. And number three, you know, people want time, but if you can extract a significant amount of time with a physician, that's like golden.
SPEAKER_02Uh Dr. Jonathan Bushman and our uh new friend Dr. Sean Stanga. Uh and Jonathan, it's very exciting to me because uh, you know, in our travels and our work, uh, we meet different people, we meet new people. And uh in a recent event uh that I was at, uh I met Sean, and uh when he told me what he was doing, I was like really captivated because it's a new specialty that you know we talk about orthopedics, we talk about general surgery, we talk about different things that can be directly contracted where uh patients and uh the self-funded plans are going direct.
SPEAKER_02But uh Dr. Sean Stenge has a new one for us uh in terms of those direct contracts uh with uh allergy uh and and algebra uh that kind of care. And so anyway, uh Jonathan, welcome to the program. Uh any introductory thoughts from you yet?
SPEAKER_03Yeah, I mean, I'm I'm really excited to hear from Dr. Stenga. So I, you know, being in direct primary care for eight years, um I've seen a smattering of direct specialty care that continues to grow, and I'm really, really surprised, not just surprised, but really excited about how many specialties are starting to go out and say we can do this and we can do it better, and and we can make sure the patients get what they need. And that to me is exciting, and I continue to find myself uh I'm I'm growing my my toolkit with my partners and colleagues from around the nation who can who can do this stuff for us.
SPEAKER_03So yeah, I'm excited about this, Dr. Stenga.
SPEAKER_00Yeah, thank you very much for having me. This is exciting to be here, and it's exciting to kind of um tell you about my journey and what's led me to this point and uh what we have in plan for the future.
SPEAKER_03Well, that's a little bit, tell us a little bit about your your background, Dr. Stenga. Like you you you practice in Iowa, but give us a little bit more of like how did you get into medicine and allergy and why?
SPEAKER_00Yeah. Um, historically, uh I think that uh so I I did a pediatric residency by default and um you know loved general pediatrics and actually was this close to becoming a neonatologist. Um loved the high-risk newborns and the intensity and the procedures and just being, you know, uh incredibly involved with with people in such a vulnerable point of their lives, you know, from parent standpoint. And um, you know, that was in the in the early 2000s, and I we were kind of watching things and how how hospitals were were evolving at that point in time and tort reform and um the legal uh ramifications of high-risk care.
SPEAKER_00And um, I also took a look at the lifestyles of a lot of you know doctors surrounding me and the people that trained me as well. I was like, wow, you know, natology is pretty rough. That was before really you got a whole lot more NNP involvement and uh restructuring of ours and whatnot. But I I had a a passion for allergy as well. Um I'm allergic to everything. Uh grew up with, you know, probably about 20 plus years of allergy shots and dealing with chronic urticaria and a number of other ailments, and that seemed to fit me well. And I I felt like I could make, you know, just as good of a difference knowing that, you know, I actually had walked that walk to be able to speak that um language to patients who are really struggling.
SPEAKER_00And I had some really good mentors in residency and um did a uh an elective rotation at Children's Mercy Hospital for allergy, and that's ultimately where I decided to do my fellowship. And so after Kansas City, um I took my first position in North Dakota, in Minot, North Dakota. So way up at the top of the world. And there's two seasons up there there's summer and there's winter. And the summers are beautiful. I mean, you know, it's 80 degrees, low humidity, uh, lake sports, fishing, green.
SPEAKER_00You bet uh it's awesome. But the winters are pretty rough. And um, you know, we spent about 12 or 13 years up there, and uh my wife and I uh finally made the decision to come back to Iowa where I did my residency and where she's from. And it was uh it was a very um complex process to make the decision to to do what we did in our in our jump from uh being a hospital employee to going into private practice, but not only private practice that everybody knows, but direct care, private practice.
SPEAKER_00And not only direct care, but direct specialty care. So I kind of niche down really quickly in in the order of things here. And to to kind of go into detail, would you like me to kind of tell you the whole process behind it? Yeah, please. Well, you know, being in a in a in a good environment like North Dakota, um worked with a lot of wonderful people and some great colleagues, and I had a lot of positive interactions with with patients and administration. Um and you know, we we you know were structured on what you would consider the typical 90s um hospital uh pay algorithm on a production-based schedule of what life used to be like before um RBUs kind of entered the scene.
SPEAKER_00And once that happened, the dynamic totally changes. And I've heard this from other physicians who have been involved in in this kind of a scenario as well. Dr. Bushman, yeah. And all of a sudden, you have benchmarks, and these benchmarks are not conducive to patient care, unfortunately. Um I suppose it's the way hospitals survive, and it's the way that you know they are able to maximize the profit. Um to be able to afford um their services, uh both on an outpatient and emergent level, with the amount of write-offs that they have to do.
SPEAKER_00And so when RVUs came into play, everything changed dramatically. Um these benchmarks and these baselines that you had to you had to meet, these minimums that you had to hit, uh became um inherently uh necessary for you to maintain a contractual agreement and a structure. And researching this down the line, uh I had interacted with several allergists and even even locally here in Iowa who were actually terminated because they weren't reaching those minimums.
SPEAKER_00Um Allergy is not a subspecialty in general that works well with RVUs to begin with, because the CMS standard that they've established for RVU uh based on, let's say, per scratch test that we do, it absolutely makes no sense at all. Um and when you try to set a minimum for an allergist to meet a certain number of RVUs in a contracted year, it's darn near impossible unless you understand what it takes to see a typical allergy patient, the time that goes into seeing that patient, and the complexity of the service.
SPEAKER_00It's not rapid fire in and out. It's it's a it's a it's a drawn-out skin test, it could be a patch test, it could be a food challenge. Um and the insurance reimbursement reflects it fairly well, but the RVU system does not. Um and the insurance reimbursement is changing dramatically too. We'll save that for a little bit later. But coming from a hospital system, as a hospital employee, I I saw these changes going into effect, and I saw what it can do to patient care uh and what it does to the physician practicing in that in that realm.
SPEAKER_00Now, it doesn't apply to all specialties. It may work out better for surgical disciplines and hospital, you know, dependent practices that need, you know, that have more hospital integration and more OR time and whatnot, because those RVUs are differently. But for allergy, it is a disaster. And you're seeing more and more allergists who are employed by hospitals just forgetting about skin testing. We're not gonna do skin testing anymore because there's more RVUs that can be generated by seeing a new patient level four than doing an entire skin test that takes an hour and a half or two hours.
SPEAKER_00Thereby, the physician makes way more RVUs by just seeing more and more patients and saying, well, it's gonna send off a blood test, which is not um the uh is not not the preferred method of of doing an initial evaluation for a for a hypersensitivity reaction. And so more and more doctors are doing this, and this just compromises patient care. It also produces that carrot dangling effect where you know it's like, okay, the more patients I see, the more new patients I move through, the more RVUs are possible. And that's not conducive long term to I think a higher standard of patient care from a time-based standpoint, interaction.
SPEAKER_00Um being a good historian, when I was in medical school, a neurologist told me a long time ago, I said, you know, the biggest thing you could ever learn about being a specialist is being a good historian. How the heck can I do that when I'm on an RVU basis and I need to churn, I need to I need to move people through so that I can generate that minimum to make my salary, number one, and and you know, shoot for a bonus. Um that's not right. That's not right. And I looked at this and I looked at allergy and I looked at, you know, some other potential employment opportunities with larger employers uh in in the Iowa area and some hospitals.
SPEAKER_00And the conclusion I came to is that nothing is nothing is perfect right now, nor will it ever be in the current environment, and nothing is set up for success from a long-term viability standpoint in a private practice. So that's why you've got a lot of different subspecialists, analogists included, picking up cash pay alternatives to kind of supplement things, because they are watching the multiplier change and the standard being set by Medicare affecting downstream all the private payers who are deciding not to code appropriately for 95165, which is our allergy shot code.
SPEAKER_00Or they're putting imposing limits that they don't understand. You can only bill for this many. Well, it turns out that the average number just to get the patient built up on a series of injections is this much, but you're only going to pay for this much. So that means every patient we put on allergy shots, we're gonna be in the red. That doesn't work. And that's because the people behind the scenes don't understand what limitations they're putting into effect when they're writing these policies to begin with. And so ergo erupts an entire downstream cascade of back and forth arguments and negotiations and talking to people and trying to get through and even lawsuits to try to get this organized.
SPEAKER_00Did I want to do that? No. Um and so it became clear to me that there is only one future pathway that guarantees the long-term viability of a practice to even exist, and number two, that guarantees adequate, dedicated, one-on-one patient care, and that's direct care. And in this case, instead of DPC, we're going DSC, direct specialty care. And uh, John, you mentioned before that you've seen this start to show up.
SPEAKER_03Right. Yeah, and and you know, if you don't mind, Dr. Sting, I want to I I don't know if you're familiar with the RUC through CMS. Uh enlighten me a little bit more. Yeah, no, no, this is great. And I think for our audience, some people have probably heard this reference, but I want to give you a little bit more background of what the RUC is. So the the RUC is the relative value scale update committee or the RVS Update Committee, R U C RUC, and it's through um CMS, and they're basically an advisory board to CMS that meets and reviews the RVUs and makes recommendations recommendations to CMS about the relative value of a service.
SPEAKER_03And they are they are um you know meant to look at the cost and time involved to do that type of a service so that the reimbursement is um fair, right? Now, you're the first allergist I've ever talked to about this, so to hear you describe what you just described um made me really, really curious. So um there is not an allergist or an immunologist on the RUC. There's 32 members of the RUC, 29 of them are voting, 22 of them are permanent seats, and those permanent seats come from basically all the um boards of medical specialties, right?
SPEAKER_03Which, by the way, board of medical specialties, if you're not reading between the lines for specialty care, most of that permanent membership is based on the appointees by boards of specialties, right? So, me as a primary care doc, like what you're describing is so super common in primary care. I haven't heard it a whole lot in specialty care, but specific to your specialty, you don't even have a representative on the ruck. So then there's four rotating, so there's 22 of those permanent seats, four rotating seats, which is two internal medicine subspecialties specialists, an additional primary care, and then one other specialty seat through the AMA.
SPEAKER_03And then there's six leadership tiers. Again, they don't actually carry the final vote, CMS does, but um CMS typically takes their direction. And this has been a big deal in primary care because of the lack of representation in what we consider primary care as a percentage of the workforce versus primary care as a percentage of the ruck. And like who's representing primary care at the most foundational influential level at CMS?
SPEAKER_03Not many. And in your case, you didn't have a representative on that on that ruck. So it makes a little bit of sense that things are lopsided not necessarily in our favor uh because of that. But I mean a lot of people don't know what the ruck does. I happen to be very um lucky, fortunate. Um, I don't know what the word is, that one of my colleagues here in Oklahoma served the ruck as a primary care doc for many, many years. And I got to learn this earlier on in my career. Um, and he talked about this all the time, about how, man, I'm one voice.
SPEAKER_03You know, I'm surrounded by specialists. And he was always griping about it, but at least he showed up and he continued doing it into his 70s. But um, but yeah, you you mentioned DSC, which um, you know, DPC has now become such a um almost a household term, you know, like 10 years ago, definitely not. Now people understand it. DSC is becoming um like it's almost all it's almost mentioned within the sentence of DPC, yeah, uh very, very frequently because it's becoming more and more uh I wouldn't say mainstream yet, but definitely more and more recognized and not ostracized.
SPEAKER_03And I think that's the I think that's probably the biggest thing for you is that what you're doing, you're not being ostracized or criticized by your peers or your colleagues any longer. They're going, oh man, I wish I could do that. I really wish I could do that.
SPEAKER_02Um that's that's a good point, uh Jonathan, because you know, Sean, you mentioned to me you had uh you actually have colleagues still back in North Dakota that are calling you, asking you questions, how do I do this, right? Because you told me some of those stories about you know, there's so many specialists out there that just don't know what to do. Tell us some of that uh conversation.
SPEAKER_00Well, you think, yeah, to Jonathan's point, um, what he said about the RUC, I mean, I can totally see, you know, uh what's happening there. Obviously, they it's stacked with people that are you know going to be the most influential for this for the disciplines that really need that RVU input, you know, especially surgical. Uh I mean that that's essential because you know, those those guys aren't always operating on independent surgical centers and independent practices. There's there's heavy hospital involvement. Um, and so the RVU standard does need a good degree of discipline and structure to identify those those norms.
SPEAKER_00What's frustrating is that somehow in there they can still find a way to arbitrarily assign values to other disciplines that nobody knows anything about. I mean, allergy is very specific, and the billing of allergy is very comprehensive based on the way that we do various tests and challenges and buildups and desensitizations and biologic drugs. I mean, all there are all kinds of nuances in there. Um and so a lot, not a lot of people understand it. In fact, insurance companies don't even understand it. And that was half the problem that we struggled with when we would debate them, and the hospital would debate them for the appropriate contracts, and that private allergists continue to debate them for those contracts.
SPEAKER_00Um it's frustrating that these values can be assigned uh to people, to specialty disciplines when there is no um, I guess, well-defined uh group that that knows about the discipline itself. So that is frustrating. And to take it one step further, I mean, there are integral parts of our specialty that weren't even coded on an RVU basis. Like chemical patch testing. If I do a delayed hypersensitivity patch test to rule out a type 4 T cell mediated delayed hypersensitivity reaction, like nickel allergy or rubber allergy, that's not even coded in the RVU standard.
SPEAKER_00I can't even find an RVU value that's assigned to it. Um and when I looked at different employer contracts here, I said, let me see the RVU schedule assignment for allergy. Well, guess what? There's a huge procedure. There wasn't even so I if I do that, I don't get any RVU value for that then. So I guess I might as well not even do that. And meanwhile, this patient suffers with a chronic rash from some unknown dermatologic substance, you know, some cosmetic or something like that. We can't figure out, oh, it's colofany or if it's balsamapuru. No, we just won't be able to figure that out because we can't pay for that.
SPEAKER_00So, anyways, to your point, um, yes, the uh the the idea of of being um an allergist in in a in an area where you know there's two to three allergists in the entire state, um, and then coming to Iowa where it's a little bit more saturated, taking that leap, that decision to move out of insurance altogether, yeah, it turned heads. And you know, people I had I've had people call me and be like, you know, are you crazy? What are you doing? Some people say, I give you a 90% chance that you're gonna be converting back to insurance, you know.
SPEAKER_00Uh, you know, just the confidence is is there, but the curiosity is, I think, more ubiquitous. And people want to know, well, number one, how's this gonna work? And how did you set your prices? And who's gonna do this when they're already buying insurance? And there are easy answers to all of those. You want me to run through them? Absolutely. I was gonna say, I hope you'd tell us what those easy answers are. Yeah. Yeah. So number one, who's who's gonna uh who's uh like how how do you do this and who who's gonna come to this?
SPEAKER_00Well, it's the people that have insurance. And number one, I think I think everyone needs to realize that, you know, um most people who who who understand a little bit of direct care know that it's not for everybody. And some people will always have a smack down to it, and they will always be resilient to it, be like, nope, my d I'm paying a premium, and so that means that I should be able to see a doctor anywhere I go, and that my services should be covered. That is only true to a certain extent, and at this point it's descending more into catastrophic coverage anyways, but the outpatient scene is becoming more and more uh it's disintegrating more and more uh as uh uh every calendar year when it comes to you know reimbursements for practices.
SPEAKER_00So what people are valuing, the reason people are coming to direct care is because number one, the wait time, they don't have to wait nearly as long to get in to see us. And number two, the transparency. People don't want to have a ill-defined um payment plan set up before them when they walk into a uh an office, a specialty office, and they don't know how much the procedure is gonna cost. Half the people don't even know what a deductible is, and they don't know what an out-of-pocket maximum is, and then they get a bill three or four months later, or the hospital messed up, or the billing department, whatever.
SPEAKER_00So they like transparency, and transparency is exactly what you can achieve with direct care. Ergo, we have all of our prices listed online. Um everyone can see exactly what an allergy test costs, what a 60-minute visit sit down, sit downs cost. And uh and and and number three, you know, people want time. The most valuable thing in life is time, including your visit with the doctor. If you go in and you don't get your questions asked, uh answered, you feel you walk away feeling horrible and you're upset and you don't really know what the plan is.
SPEAKER_00But if you can extract a significant amount of time with a physician, that's like golden. And so people who understand the model of direct care understand that time comes with it, and that that's a huge advantage. And so it's the people that understand what we offer are the people that are coming to see us. But there's a caveat to that, and that is ignorance. That is uh unintentional and just you know uh just a general ignorance because people don't know what it's about.
SPEAKER_00So half of direct care is education and telling people what DPC docs do and what DSC docs can do. Um so it's access, it's transparency, it's education and time. And then the other part was how do we how do we price this? I mean, how do we figure this out? So I cold called every allergist in the state, first of all, and I was like, what's your cash charge for this, this, this? Um, I, you know, and honestly, and then I I did some other research into um typical insurance collections, what physicians are billing to insurance is what the reimbursements are.
SPEAKER_00I even just polled people, what would you expect to pay for an allergy test? And then based on all those metrics, we come up with standards. And there are other direct specialty allergists in the country as well. And so I'm able to use a baseline with their pricing as well. And you know, we kind of observe a general standard based on inflation, the costs of our scratch tests, the costs of our extracts, and we have to price, you know, appropriately. Um and so I think that that that is easily uh achieved, but just by doing your dedicated research.
SPEAKER_00And people are comfortable with that because they they they ascribe, they put their money where they ascribe value to, whether it's the apps on their phone, or it's the cosmetic injections, or it's the GLP ones, or it's the IV hydrations, or any other cash-paying business that you can think about, right? Versus what about your child that's coughing all night long that needs a pediatric specialty asthma assessment, or who needs a biologic medication that you know is probably not gonna come from anybody but a specialist, or who the guy that's breaking out in severe urticaria, who's been on antihistamines for the last two weeks at super high dose, nothing is fixing it, and it's probably some immune-mediated situation, and you need to see a specialist.
SPEAKER_00Well, guess what? It's gonna be two months. Well, here's direct care come along, and you can get in right away, and we can treat you, and we can take an enormous amount of time with you. And and so it's not, it's not anything that is the physician's fault. I had this conversation with my colleagues who are in allergy inside the insurance system, and they're looking at me like, man, is this gonna work? And number two, they're also like, well, how does that even work? I was like, I'll tell you, the overhead is dramatically decreased. I don't have to lose a margin to a billing company.
SPEAKER_00I don't have to pay coders and prior authorizations, I don't have to deal with referrals. The paperwork and the administrative work is out the window. All that time goes back to patients. And they understand that and they love it. And we do too. It's it really brings all this joy back to specialty medicine and to practicing the way it should be. And this is when I'm going on TV talking about, you know, and so people are kind of understanding this. So I hope that brings to light some of the sentiment.
SPEAKER_02Well, and that is so awesome because at the very foundation of that is about patient care. You're helping the patient, you're giving them what they need, you're giving them the time, giving them the test, whatever, and you're fairly reimbursed, you're getting the money that you need to stay alive, to fund your business, to take care of your family. Uh, everybody wins. The two key stakeholders, the doctor and the patient, they're winning. And that's what it's all about. That is so awesome.
SPEAKER_03You know, as you're as you're telling that story, uh, Sean, I I had to think about this. Like when you think about DSC, I was going through my head of all the different ones that I've met or have seen or uh come across. And by far and away, what we see is those non-procedural, and what I mean is not hospital procedural specialties, right? So rheumatology, endocrinology, allergy immunology. Uh we haven't seen gastroenterology, there's too many scopes still.
SPEAKER_03Um, we haven't seen a lot of the the heavy procedure-specific specialties, but this makes so much sense. And um, you know, you can look at the the various different, you know, kind of pay scales of where specialty cares come out, and you can look at the same, like you could you can pick out and know where the DSC movements can go based upon that, because you can see someone who's done one to three additional years in training versus uh family medicine or general pediatrics or general internal medicine, um, but yet the numbers look the same, right, across the board.
SPEAKER_03And this is a good example, you've given a good explanation of why that is. Um and it's nuanced obviously in your world to allergy immunology, but um, you know, I had kind of laughing to myself as you're saying to people with their insurance what they don't understand or that they defend their insurance so much. And what what I what I sometimes say to them is you you realize you're defending the decision that you made to give somebody else your money, believing they could spend it better than you could. Now, we don't have to get into politics, but I like to keep as much of my earned income in my pocket because I believe I can spend it better than giving it to certain government sources.
SPEAKER_03Right? So, I mean, that's a philosophy, but the point is kind of the same, which is like, okay, that premium is really just the transfer of your dollars to someone else for them to take on quote unquote risk, which they do, but they're really now in charge of the prices. They're in charge of the um procurement, so to speak, of who you can or can't see. You've given up a lot of autonomy when you gave up your cash to them to direct your healthcare. And so by taking that element out and saying, I actually believe you can spend your money better than your insurance, and if you need to carry an insurance, which I also promote, but you can carry an insurance that complements for the big things that you can't otherwise make good decisions or you need their help to do, right?
SPEAKER_03Um people don't frame it like that very often. They're like, you're just giving somebody else authority to spend your money.
SPEAKER_00Yeah, I I would agree. I would agree. And uh and it it's severely limiting to to the scope of practice as well, I think, with uh with regards to the things that you want to pursue, the things that take time to pursue. Like for instance, I had I had a patient the other day come in with a concern of a very specific medication reaction, or you know, something you wouldn't you know expect the other day. And nobody in this region would see that.
SPEAKER_00Go to the university. We don't do that. Why? Because they don't get reimbursed for that. They don't get reimbursed for the time that it would take. And so when when when time is on your side and everything is triced priced transparently and a new patient visit is a new patient visit regardless of the of the uh the type of visit, and a skin test is a skin test, regardless of the type of skin test, or you or if you've bundled your packages, which we're actually moving towards, um then it doesn't really matter. You can see everybody and you can be happy to see them, and you can investigate it and and make contributions to the literature for weird reactions.
SPEAKER_00And it's like versus, okay, I'm just gonna focus on what I know insurance is gonna pay for because that's what's gonna drive revenue and that's what's gonna keep me alive. And it's not that doctors fault. It's not like they don't want to help people with weird medication reactions or or very odd rashes that need, you know, very specific um therapeutic uh personalized patch testing. It's just that they don't get paid for it. So they're neglecting a part of their specialty that otherwise probably would be pretty cool to dabble in. And when you're when you're not having to conform to that, then your your discipline is not so limited in how how you can practice.
SPEAKER_00And that kind of goes into the other part of our of our care. I know Troy was interested in that too. If if if you wanted me to talk about that, that's our our innovative desensitization.
SPEAKER_03Yeah. Well, I'd absolutely love to hear from that. And and just to remind you, if you're if you hadn't thought about it, we are two Oklahomans. We happen to know people with allergies.
SPEAKER_01Right.
SPEAKER_03There's so many allergies. Uh and I know you're talking about some some of the maybe less mainstream allergies that you're testing for and trying to figure out. But like we uh I have a great colleague locally that's an allergist immunologist, uh, but he splits time between here and another community, and um, you know, he is absolutely responsive, but he's he's it. Like he is it for the entire northwest side of our state. Yeah. And it's like that's just it's so hard.
SPEAKER_03And there's so many things that um, you know, while I know if I get a patient in front of him, um, he's gonna get the answer and help the patient. At the same time, there's a lot of things that we know what needs to be done. Um, he's not standing in the way of that per se, except for sometimes it's the testing, sometimes it's the it's the other things, or even, hey, we know what's wrong. We just need we need the desensitization, right? And um, you know, um I'd love for you to tell us kind of what you do and then even how that how that um works in collaboration with primary care.
SPEAKER_00Sure. Sure. Uh to your point exactly, uh patients need this procedure, they need this desensitization, they need this thing that is not achievable inside of a a a standard conventional practice because it's it's it's either not paid for or it's not worth the time. That's why at the University of Iowa there's a wait list of like 16 months for an FPIs challenge. I mean, it's like what so we can do that. You know, yeah, that's what I that was was the latest interaction that I had from um from some colleagues who worked over there.
SPEAKER_00So uh and they're the very again, very specific niche procedures that are you know something that would be performed, you know, just any day. Um but to that point that when when you talk about um you know looking at how how somebody can expand um with direct care, uh especially when we're talking about crossing state lines. Um I'm also licensed in 25 states, and I I did that on purpose to try to expand this model because we we can do that. And telemedicine is is highly efficient inside specialty discipline, and we we know the statistics of reduced morbidity and mortality with telemedicine access to specialists.
SPEAKER_00If you don't have even asthma, I mean, yeah, it's it's it's nice to have spirometry and F E N O and to be able to listen to the lungs, but the studies, even out of children's mercy, show that telemedicine has a huge role in maintenance of asthma and preventing exacerbations and hospitalizations. Because, I mean, you know, you're extracting it from the history, and you can get a ton with being a good historian and telemedicine model. So we've opened that access with direct care and direct specialty care for that matter, to our telemedicine footprint. And I'm licensed in Oklahoma.
SPEAKER_00And when you talk about, you know, one in three or one in four adults and children having some form of allergic atopic disease in the United States, that's an incredible volume that really is yet to be fulfilled. And you've got physicians and specialists burning out. Look at the JAMA reports for physician burnout and what's happening. Right. And less and less people, I mean, there's a shortage of allergists, of course. Um, there's a short, you know, look at all the different subspecialty disciplines and what's going to happen in the next 10 years if we trend down this way, down this road, of having to cram more and more patients into a small time frame and burning these poor people out, there's only one answer.
SPEAKER_00And that's to adopt a different system. And and and and for a discipline like allergy, moving out of insurance is a is a is an easily easy um uh goal to achieve. So one of the things that Troy was talking about that I mean, we're we're very excited about this as well. And this is something I've always wanted to do that I couldn't do inside the hospital system. Um it's a form of desensitization. And it's getting involved in things that are off-label but have excellent clinical data and efficacy, and how many procedures are being performed, how many drugs are being administered, how many peptides are off-label right now that people are jumping in.
SPEAKER_00Off-label is not a means to say, well, this is you know entirely not even feasible for the general population. No. An off-label applies to different aspects of a therapy, and when you when you explore it and understand certain elements of it, it it makes clear sense. For instance, what we're doing is called intralymphatic immunotherapy. It's a mouthful. We we actually have the trademark on a name and it's rapimmune. So it's it's easier to say rapimune than intralymphatic immunotherapy, right?
SPEAKER_00Uh and what this is, this is a form of allergy shots that is, I believe, is going to change the game. Everybody knows what allergy shots are. Allergy shots are a pain in the butt. They are a time commitment that involves desensitizing your immune system so you no longer have the allergy to begin with. You're fixing the root of the cause instead of just putting a band-aid on it with antihistamines. And what it takes is a big time commitment, once or twice a week to the allergy doctor's office for three to six months.
SPEAKER_00That's your buildup. And then we slowly space you out over the course of the next six months, and then you're on that maintenance for three to five years. Five years is great if you can if you can manage it. It comes to a total of about 104 to 109 injections if you abide by current protocol. And each one of those, you have to wait a half an hour in the allergist office for risk of anaphylaxis, not to mention your drive time, the check-in time, the return drive time, and how much lost employer cost is there too, missed work time with those things, or missed school time.
SPEAKER_00Which is gonna say couple that with school. Yeah. Yeah. We try not to pull kids out of school for allergy shots, but it then it gets just then it gets a burden at from that three to five time frame when everybody floods the allergy doctor's office. So what are we doing to do about that in different well the the biggest advantage here, and the studies have have been very robust for the past 20 years, initially originating out of Europe, uh, is to take a different approach. And instead of putting that allergy shot right into the back of the arm and the fat, we go right to the lymph node under ultrasound guidance.
SPEAKER_00We use a much smaller amount, and it requires less, less, less frequent dosing, almost a thousandfold less volume of allergen extract for the entire course of a typical shot protocol. And we do it in three injection visits. And the efficacy shows comparable to a three-year course of allergy shots in that compressed period of time. And not only is this such an advantage for patients, it's a massive advantage to employers who are paying for the deductible that gets it that you know, all the the pre-everything that's involved, the patient is required to meet their deductible, their copay of$70 to$80, marked up if they're in a hospital scenario.
SPEAKER_00Um, what happens when the allergy vials expire? What happens when they miss their visit and they got a reset, they got a remix? It's a nice deal if you're an allergist, and I practiced in that system for 12, 13 years. But for the patient, you know, you you gotta come in. Otherwise, they're gonna expire. That's why, that's why they have to bill it up front when they when they mix it, because you can't take that risk on as a clinic. So this is a revolutionary new way to treat seasonal allergic rhinitis, not with not only pollen, but animal, mold, dust mite.
SPEAKER_00It's not for food, but it's for the most common condition that we see from an allergic standpoint for the majority of the population. And the reception we've got here so far in the Midwest has been tremendous.
SPEAKER_03No, that's awesome. Um, so you mentioned I'm gonna I'm gonna go clinical on us for a moment here, Troy. Yeah. Um so you mentioned uh allergic rhinitis is the primary indicator. Um is it is it is it something where it's um you know hard to treat or not responsive? Like is there anything that prevents you from going straight to some form of therapy like that? And then what's the long-term or suspected long-term after-treatment results of it?
SPEAKER_00Yeah, durability. Um there's not any uh, I would say, uh when we talk about indications, so somebody who typically would be put on immunotherapy to begin with would be a patient that is refractory to standard therapy. So you can gain control if you know 70% of the population can gain control of their allergies by taking over-the-counter meds if they're diligent. Antihistamines, higher dose antihistamines, nasal corticosteroids, nasal antihistamines, sinus irrigation. You've got all these available opportunities over-the-counter that work well for people.
SPEAKER_00Um, but there is a good number of patients who have refractory symptoms. And once you meet that requirement, typically, uh, they immediately become a candidate for desensitization. And that's long been the method that we've used to treat these refractory patients. Um it spills over because the data extends to people who have allergic asthma and even eczema. And there's even good research that shows when you control somebody's severe aeroallergen disease, that it improves other facets of atopic illness as well, like eosinophilic esophagitis.
SPEAKER_00You wouldn't think that. Um so the indications are clear once people have failed therapy, but there might be the average guy who just doesn't like to take medications or can't remember to take medications or has side effects, significant sedation from satirizine, which is reasonable. Um and that's an approach you can take to doing desensitization immunotherapy as well. Um and then the durability that you asked about. So we we do have we do have excellent data showing durability um comparable to an average course of allergy shots, which is roughly a minimum three years.
SPEAKER_00We try to push for five years to extend that durability when we put somebody on allergy shots. But our studies and what we find in the in the in the literature shows durability indices comparable to what a conventional form of allergy shots would be. And so we don't expect people to have refractory symptoms once they've finished the three-month course of intra-ymphatic immunotherapy. But we do offer what we consider a booster, kind of like a booster dose, if it's needed. Most of the time it's not needed. The following spring, symptoms come back, we reinject a little bit more of a stimulation to the immune system, and they can start manifesting a little bit uh more desensitization at that point.
SPEAKER_00Um there's even some there's a pretty good study in the literature that shows dip durability almost out to 20 years after one course of intralymphatic immunotherapy. And that was really impressive to read that one. Um and that's kind of one of the mainstays behind you know this philosophy as well.
SPEAKER_03How does this differ from the sublingual or or oral um desensitization techniques?
SPEAKER_00Well, I'll back up real quick right there, and I'll go back to the um to the to the inter-lymphatic approach. Uh the the one thing that makes this off-label is we're not using any different allergen extract. We're using the same allergen extract FDA approved that we use for standard desensitization. What is off-label is the delivery method. We want the allergen extract to go to the lymph node. It has to go to the lymphatics inside the subcutaneous tissue. Eventually it gets there, but it requires lots of injections.
SPEAKER_00And you have higher risk of local reactions and more anaphylaxis with conventional shots versus versus intralymphatic, because you're encapsulating inside that lymph node. And so the off label is just simply the route of delivery. Instead of going in the fat, waiting for it to get to the lymphatic, we are going directly to the lymph node.
SPEAKER_03So I'm sure I'm I'm sure that based upon your childhood history that you're you're thinking you've learned all of this way too late in life. And where was this when I was growing up, right?
SPEAKER_01Exactly when I was still where were you five years ago, is what I want to know.
SPEAKER_03Because my my uh oldest is about to get married. She's 20 and uh young to get married, but she's she's awesome. But at 15, she had to come off the soccer field because she had a panic attack. And it wasn't really sure what's going on, but then she kept having them. Practice, games, what is going on? And she had she had asthma. Had never had any of this. She had allergic rhinitis, like always, that was fairly decently controlled with over-the-counters, but never got out of hand, and then all of a sudden she's coming out of competition.
SPEAKER_03Like, what is going on? And I didn't even, as a physician, recognize it as asthma. I really thought she was just kind of panicking. But she was I just can't breathe, you know. I'm like, uh-huh. Anyway, so long story short, she ends up going on to desensitization, the traditional methods. Um, she had um anaphylaxis twice from the uh immunotherapy or the desensitization therapy. From the shower. One of which was the strangest thing because it was like a day and a half after, which was a little odd.
SPEAKER_03But um, she comes to my bedroom at 10 30. I'd just got into bed, and she goes, Dad, I need you to take me to the ER. In that voice right there, Dad, I need you to take me in the ER. I can't breathe. Well, surely you can breathe, you just talk to me. Take me to the ER. And um long story short as well, it took me 10 minutes to get ready to go to the ER, because I'm like, this is nuts. I sat in the parking lot for 20 minutes because as even as a physician, I'm going, You look f like, yeah, you're you're just congested, like, you know.
SPEAKER_03Surely this isn't a big deal. We walk in, the the paramedic that was doing the intake looks at me and he knows who I am and he's looking at her, and what are we here for? And I said, anaphylaxis, and he goes, anaphylaxis. And I said, Yeah. And uh I said, I'm her dad tonight. I'm not a physician. I'm here for her. And she says she's having anaphylaxis, so that's what she's having. And we walk back to the ER Bay. ER doc walks in, takes one look at her uvula. It's big and swollen.
SPEAKER_03She's tight and wheezy bilaterally. And he's like, She's got anaphylaxis. And she avoided the entirety of the uh she didn't have to have epinephrine in that moment. He gave her everything else and she recovered well. But it was good, like for me, having been, I mean, like taking care of people all the time. I see this all the time, and don't even recognize it in my own own daughter, you know. Um, and and it was literally as a result of the you know traditional desensitization therapy.
SPEAKER_03Isn't that crazy? That's crazy. And it probably only happened because I'm her dad and a doctor. That's probably the only reason. That's how it always happens, right? Yeah. Um yeah, but yeah, I'm thinking, where were you five years ago? This would be phenomenal, right? So do you partner Do you do all of your rapimune um uh therapy there in you on on site, or is this something that you do with other clinicians?
SPEAKER_00No, it's all on site here at Alogenics, and we are uh we're excited to be the only provider in uh pretty much the upper Midwest. Historically, there were several providers kind of scattered throughout the United States, mostly confined to bigger cities, um, hard to find, uh way out of crazy pricing. Um, but as this has slowly been picked up by more and more allergists, and the you know, more and more training is being offered, it's not integrated into the fellowship programs yet uh because it's still considered off-label. Uh it's becoming a a um something that that it is earning a lot more credibility and respect.
SPEAKER_00Uh just I think among the medical community in general. But if you ask any private practice allergists, they're like, oh, I've heard of that. It's in the literature, but how the heck am I gonna do that? We gotta invest in a$30,000 ultrasound machine, and then you gotta go figure out how to get trained in you know doing ultrasound guided injections, and then you gotta demo and practice. And it it's it's a it's a lot. And so I think the average allergist is not really gonna jump on this, but what it means for the patients is tremendous. Um so we're excited to to to bring it to Iowa, and I could see, you know, some expansion potential here as well.
SPEAKER_00And you know, I've been talking to Troy about you know potentially expanding this, you know, as more of a remote option if there's a destination need for it that can be you know scheduled in in aggregate um because it is entirely uh mobile. It is not something that requires massive. Yeah, your our ultrasound diagnostics are are are portable and extremely high resolution. And this is not point-of-care iPad transducer models. These are real GE venue fits with uh high resolution Doppler um needle acquisition mode, everything.
SPEAKER_00It's really uh something. And it's been such a fun experience to to to bring this to people that have never heard of it. And that's kind of one of our the nuances of of this is that nobody knows about this. Um and how do you advertise something that people don't really know about?
SPEAKER_03So for the entirety of my career, and we probably went through school uh pretty similar times, but um, through the entirety of my career, I've had the patient, you know, every few months that comes in and has this history of going to Europe for some treatment, you know? And uh so it's not an uncommon thing to hear of like, yeah, they've been doing this in Europe for 10, 15, 20 years, it's pretty well accepted. Like this is kind of the normal thing there. And uh we in the US, sometimes it's the FDA's fault, but we in the US we're a little slower uh uh to adopt some of that stuff.
SPEAKER_03So um that's cool. Do you know of anybody uh or had heard of anybody actually making sort of the the trip to Europe to do this form of therapy as well? Or is that or is it just kind of where it was uh initially uh um integrated into practice?
SPEAKER_00I think about a decade ago that would have been more commonplace, but now you know if you search online, you can find providers. In fact, we're I'm part of a network that's that's putting together a uh a national provider website specifically for this um service. So we're excited. Yeah, and we're actively collecting data, you know, using, you know, SNOT 22 scores and you know, before and afters and you know reaction data, I mean everything to eventually put this into the literature to help mainstream this a little bit more.
SPEAKER_00But for now, I think it's you know it will stay off label until we can get you know the funding to push this through. But that that's another thing is I don't know how easily that will happen either, because we're using very, very small amounts of allergen extract. And so that's cost prohibitive for for um researchers.
SPEAKER_03Yeah. Yeah. Yeah. I mean that you you mentioned peptides earlier, but that's where we're at with some of the not necessarily the GLP ones, but like all the other peptides that are becoming much more um mainstream or at least talked about, right? Um yeah, there's no money in that. Like they're they're peptides. It's not that hard to make, they're they're cheap. Um nobody's gonna put money into research on that if they can't capitalize it a thousand fold, like they do everything else. So that's incredible. Um I'd like to wrap up a little bit with you, uh, Dr.
SPEAKER_03Sting. I mean, uh number one, I want to tell you how much we appreciate um you coming on with us, this conversation. And I want to say also proudly um to to to welcome you, even though I'm late to the party, welcome you to the world of direct care. Um one of my favorite things I've heard you say today was that your joy was restored. And it's an it's an it's a part of of medicine that many patients and brokers, employers haven't held in as much regard as it matters, which is the people taking care of your people or the people taking care of you, when they are finding joy in their work, the level of care, the level of satisfaction, and the outcomes all follow.
SPEAKER_03And so um I'm I'm happy for you, I share in the joy, and um really appreciate you um and what you're doing, and really look forward to seeing where your business takes you because um I I'm right there with you in the optimism that uh treatments like this and and and the approach to care like this is only going to um expand.
SPEAKER_00Yeah, totally agree. And I thank you guys very much for having me on here because there's there's there's I mean, this is a topic that we could have you know five more podcasts about. There were so many things we didn't even touch on, like our relationships. Absolutely DPC docs, and and then what about the advantage to employers and you know contracting? Uh I mean, there's so many different things that you can apply to direct care, which they're already doing in a number of different disciplines, and they're bundling these therapies and they're bringing them directly to employers. They're saving small employers gobs of money.
SPEAKER_00Um I know you guys know all about that.
SPEAKER_03Not to mention Alpha Gal. I wanted to bring up Alpha Gal. There's just like a time for that. That's a whole hour of discussion. And it's becoming recent in in parts of Oklahoma as well. So anyway, yeah, no. Uh we'd love to have you back and uh appreciate the time you've given us.
SPEAKER_00Thank you very much. Appreciate it. Thank you both.
SPEAKER_02Well, now, Jonathan, you see why I wanted to have uh Dr. Stang on the program. No, absolutely great uh introduction, and uh Sean, we thank you for coming on, and uh we appreciate the work you're doing, so thanks.
On this episode of Patients Win, Dr. Jonathan Bushman and Troy Reichert set aside business models and policy talk to get personal, digging into the real patient stories that have shaped their mission in healthcare. From...
Welcome to another episode of Patients Win. Today, Dr. Jonathan Bushman and Troy Reichert are joined by Dr. Lane Peyton, a passionate psychiatrist from Oklahoma City, known for his dedication to integrative medicine and...
Welcome to another episode of Patients Win. Today, we’re joined by Dr. Saju Joseph, a renowned surgeon based in Las Vegas with a fascinating journey from surgical training in Boston to an extraordinary fellowship in...
In this episode of Patients Win, Dr. Jonathan Bushman sits down with longtime friend, colleague, and next-door clinic neighbor Dr. Charles Jantzen for an honest conversation about resilience, burnout, and rediscovering...
Welcome to another episode of Patients Win. Today, we explore what it truly means to move healthcare upstream, shifting the focus from reactive disease treatment to proactive, whole-person care. We’re joined by Dr....